Literature DB >> 18185135

Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema.

Ingrid U Scott1, Neil M Bressler, Susan B Bressler, David J Browning, Clement K Chan, Ronald P Danis, Matthew D Davis, Craig Kollman, Haijing Qin.   

Abstract

PURPOSE: To evaluate agreement in diabetic retinopathy severity classification by retina specialists performing ophthalmoscopy versus reading center (RC) grading of seven-field stereoscopic fundus photographs in a phase 2 clinical trial of intravitreal bevacizumab for center-involved diabetic macular edema.
METHODS: Clinicians' grading scale used four levels: microaneurysms only, mild/moderate nonproliferative diabetic retinopathy (NPDR), severe NPDR, and proliferative diabetic retinopathy (PDR) or prior panretinal photocoagulation (PRP) or both. The RC scale used eight levels: microaneurysms only, mild NPDR, moderate NPDR, moderately severe NPDR, severe NPDR, mild PDR, moderate PDR, and high-risk PDR. Percent agreement and kappa statistic were defined by collapsing RC categories to match those used by clinicians.
RESULTS: There was agreement in 89/118 eyes (75%) with kappa = 0.55 (95% confidence interval [0.41, 0.68]). In six eyes, disagreements were of potential substantial clinical importance: five eyes with subtle retinal neovascularization and one with a small preretinal hemorrhage identified only in photographs.
CONCLUSIONS: Clinician grading of retinopathy severity had moderate agreement with RC grading and might be useful for placing eyes into broad baseline categories.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18185135      PMCID: PMC2377181          DOI: 10.1097/IAE.0b013e31815e9385

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  15 in total

1.  Ophthalmoscopy versus fundus photographs for detecting and grading diabetic retinopathy.

Authors:  J L Kinyoun; D C Martin; W Y Fujimoto; D L Leonetti
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-05       Impact factor: 4.799

2.  Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

3.  Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

Review 4.  Effectiveness of screening and monitoring tests for diabetic retinopathy--a systematic review.

Authors:  A Hutchinson; A McIntosh; J Peters; C O'Keeffe; K Khunti; R Baker; A Booth
Journal:  Diabet Med       Date:  2000-07       Impact factor: 4.359

5.  Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study.

Authors:  P Mitchell; W Smith; J J Wang; K Attebo
Journal:  Ophthalmology       Date:  1998-03       Impact factor: 12.079

6.  The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.

Authors: 
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

7.  Screening for diabetic retinopathy. The wide-angle retinal camera.

Authors:  J A Pugh; J M Jacobson; W A Van Heuven; J A Watters; M R Tuley; D R Lairson; R J Lorimor; A S Kapadia; R Velez
Journal:  Diabetes Care       Date:  1993-06       Impact factor: 19.112

8.  Comparison of diabetic retinopathy detection by clinical examinations and photograph gradings. Barbados (West Indies) Eye Study Group.

Authors:  A P Schachat; L Hyman; M C Leske; A M Connell; C Hiner; N Javornik; J Alexander
Journal:  Arch Ophthalmol       Date:  1993-08

9.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes.

Authors:  R Klein; B E Klein; S E Moss; K J Cruickshanks
Journal:  Ophthalmology       Date:  1998-10       Impact factor: 12.079

10.  Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1995-04       Impact factor: 12.079

View more
  15 in total

1.  Comparison of image-assisted versus traditional fundus examination.

Authors:  Kristen Brown; Jeanette M Sewell; Clement Trempe; Tunde Peto; Thomas G Travison
Journal:  Eye Brain       Date:  2013-02-13

2.  Imaging of diabetic retinopathy and diabetic macular edema.

Authors:  Ronald P Danis; Larry D Hubbard
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

Review 3.  Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.

Authors:  Maria José Martinez-Zapata; Arturo J Martí-Carvajal; Ivan Solà; José I Pijoán; José A Buil-Calvo; Josep A Cordero; Jennifer R Evans
Journal:  Cochrane Database Syst Rev       Date:  2014-11-24

4.  Morphologic assessment for glaucoma in the Multicenter Uveitis Steroid Treatment (MUST) trial.

Authors:  Sapna S Gangaputra; Michael M Altaweel; Qian Peng; David S Friedman; P Kumar Rao; C Stephen Foster; Rosa Y Kim; Susan B Reed; Sunil K Srivastava; Ira G Wong; John H Kempen
Journal:  Ocul Immunol Inflamm       Date:  2011-08       Impact factor: 3.070

5.  Comparison of standardized clinical classification with fundus photograph grading for the assessment of diabetic retinopathy and diabetic macular edema severity.

Authors:  Sapna Gangaputra; James F Lovato; Larry Hubbard; Matthew D Davis; Barbara A Esser; Walter T Ambrosius; Emily Y Chew; Craig Greven; Letitia H Perdue; Wai T Wong; Audree Condren; Charles P Wilkinson; Elvira Agrón; Sharon Adler; Ronald P Danis
Journal:  Retina       Date:  2013 Jul-Aug       Impact factor: 4.256

6.  Use of antivascular endothelial growth factor for diabetic macular edema.

Authors:  Rushmia Karim; Benjamin Tang
Journal:  Clin Ophthalmol       Date:  2010-05-25

7.  Anti-VEGF monoclonal antibody-induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis.

Authors:  Mario Saravia; Gustavo Zapata; Paula Ferraiolo; Lourdes Racca; Alejandro Berra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-05       Impact factor: 3.117

8.  Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings.

Authors:  Alexander J Brucker; Haijing Qin; Andrew N Antoszyk; Roy W Beck; Neil M Bressler; David J Browning; Michael J Elman; Adam R Glassman; Jeffrey G Gross; Craig Kollman; John A Wells
Journal:  Arch Ophthalmol       Date:  2009-02

9.  SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type.

Authors:  Ingrid U Scott; Barbara A Blodi; Michael S Ip; Paul C Vanveldhuisen; Neal L Oden; Clement K Chan; Victor Gonzalez
Journal:  Ophthalmology       Date:  2009-04       Impact factor: 12.079

Review 10.  The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review.

Authors:  John A Ford; Andrew Elders; Deepson Shyangdan; Pamela Royle; Norman Waugh
Journal:  BMJ       Date:  2012-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.